SPRING GROUP MEETING
Seattle
Immunotherapeutics Committee
APRIL 3-6, 2024 | SEATTLE, WASHINGTON
Immunotherapeutics Committee

Leadership
Co-Chairs: .................. Siwen Hu-Lieskovan, MD, PhD
.................................................. Katerina Politi, PhD
Executive Officer: .................. Anne Chi-An Chiang, MD, PhD
Statisticians: .................. Michael LeBlanc, PhD
.................................................. Katie Minichiello, MS
.................................................. James Moon, MS
Data Coordinator: .................. Matt Gospe
Pharmaceutical Science: ............. Jordan P. McPherson, PharmD
.................................................. Kimberly McConnell, PharmD
Protocol Project Manager: ............ Chris Kippola
Clinical Trial Program Manager: ........ Laura Gildner, MS

Time/Location
Thursday, April 4, 2024  1:00 p.m. - 3:00 p.m.
Room: Chiliwack / 402 (Level 4)

Agenda
1:00 – 1:20 pm Developing Predictors of Immunotherapy using Big Data
Eytan Ruppin, MD, PhD
Senior Investigator, National Cancer Institute
Chief, Cancer Data Science Laboratory
1:20 – 1:30 pm Q & A
1:30 – 1:40 pm S2101 iMATCH Pilot – Trial Update
Paul Swiecicki, Katerina Politi, Siwen Hu-Lieskovan
1:40 – 1:45 pm Q & A
1:45 – 1:55 pm S2013 I-CHECKIT – Trial Update
Krishna Soujanya Gunturu, MD
Associate Chief, Clinical Trials & Correlative Science Research, Hartford HealthCare Cancer Institute
1:55 – 2:00 pm Q & A
2:00 – 2:10 pm A151804: Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events – Trial Update
David E. Kozono, MD, PhD
A151804 Study Chair
Assistant Professor of Radiation Oncology, Harvard Medical School
Director, Thoracic Radiation Oncology
2:10 – 2:15 pm Q & A
2:15 – 2:25 pm SITC’s Resistance Data Collection Effort, led by SITC’s Immunotherapy Resistance Committee
Harriet Kluger, MD
Harvey and Kate Cushing Professor of Oncology and of Dermatology
Director, Yale SPORE in Skin Cancer, Yale Cancer Center
Ryan Sullivan, MD
Associate Professor of Medicine, Harvard Medical School
Physician Investigator (CI), Cancer Center, Mass General Research Institute
Hussein Tawbi, MD, PhD
Deputy Chair, Department of Melanoma Medical Oncology
Co-Director, MD Anderson Brain Metastasis Clinic
2:25 – 2:30 pm Q & A
2:30 – 2:50 pm Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer
Mark Awad, MD, PhD
Assistant Professor of Medicine, Harvard Medical School
Director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
2:50 – 2:55 pm Q & A
2:55 – 3:00 pm Closing Remarks

Active Study
S2101, "Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study." Drs. Hu-Lieskovan, Swiecicki and Politi.
Activation: 10/14/22.

Publications
Published/Accepted Manuscripts
None this cycle
Submitted Manuscripts
None this cycle
Immunotherapeutics Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

<table>
<thead>
<tr>
<th>Institution and Study</th>
<th>Accrual</th>
</tr>
</thead>
<tbody>
<tr>
<td>Essentia Health NCI Community Oncology Research Program</td>
<td>1</td>
</tr>
<tr>
<td>Heartland Cancer Research NCORP</td>
<td>1</td>
</tr>
<tr>
<td>New Mexico Minority Underserved NCORP</td>
<td>1</td>
</tr>
<tr>
<td>Northwestern University LAPS</td>
<td>1</td>
</tr>
<tr>
<td>Pacific Cancer Research Consortium NCORP</td>
<td>1</td>
</tr>
<tr>
<td>University of Michigan Comprehensive Cancer Center LAPS</td>
<td>9</td>
</tr>
<tr>
<td>University of Utah - Huntsman Cancer Institute LAPS</td>
<td>5</td>
</tr>
<tr>
<td>ALLIANCE</td>
<td>4</td>
</tr>
<tr>
<td>ECOG-ACRIN</td>
<td>3</td>
</tr>
<tr>
<td>NRG</td>
<td>1</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>27</strong></td>
</tr>
</tbody>
</table>